Clinical trial · no report yet · Phase 3
CAPItello-281
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
- NCT04493853 ↗
- Active not recruiting
- AstraZeneca
- 155 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 71 | |
| YouTube | 50 | |
| Podcasts | 28 | |
| X videos | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Hormone-Sensitive Prostate Cancer
- Interventions
- Capivasertib; Placebo; Abiraterone Acetate
- Arms
- Capivasertib + Abiraterone · Experimental
- Placebo + Abiraterone · Placebo comparator
- Enrollment
- 1,012
- Primary outcomes
- Radiographic Progression-free Survival (rPFS)
- Sponsor
- AstraZeneca
- Start
- Jul 13, 2020
- Primary completion
- Oct 7, 2024
- Results posted
- Yes
- Registry record
- NCT04493853 · updated Sep 10, 2026
Publications
linked from the registry- Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ; CAPItello-281 Study Group. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026 Jan;37(1):53-68. doi: 10.1016/j.annonc.2025.10.004. Epub 2025 Oct 19. PubMed 41120017